On June 24, 2026, Microsoft’s Digital Crimes Unit (DCU) facilitated the takedown, suspension, and blocking of domains that ...

The loop takes agentic AI a step further by authorizing a swarm of agents to work continuously in the background, endlessly.

Alex L. Zhang was 13 years old when he published a video game that went viral. More than 100,000 people bought the game for ...

Forbes contributors publish independent expert analyses and insights. Dr. Lance B. Eliot is a world-renowned AI scientist and consultant. This voice experience is generated by AI. Learn more. This ...

The companies at the frontier of artificial intelligence should be ready to slow down, one of the fastest-moving among them says. Anthropic, the maker of the Claude chatbot, has claimed AI systems may ...

Recursion is building an industrialized engine for medicine. It operates among biotech stocks, selling access to its proprietary platform and pursuing joint development with major partners like Roche ...

Andrej Karpathy, one of OpenAI’s original 11 co-founders, has joined Anthropic’s pre-training team. He will build a new group that uses Claude itself to accelerate the most expensive phase of frontier ...

A new frontier AI company called Recursive Superintelligence has emerged from stealth with $650 million in funding and an unusually ambitious goal: building AI systems capable of improving themselves ...

Richard Socher's new $650 million startup wants to build an AI that can research and improve itself indefinitely — and he insists it will actually ship products.

Recursive Superintelligence, founded by former Google, Meta and OpenAI researchers, is part of a growing effort to automate the creation of artificial intelligence. By Cade Metz Reporting from San ...

A London-based AI startup set up just months ago, which believes it’s pursuing the fastest path to surpassing human intelligence, has today come out of stealth, having raised over $650m at a $4.65bn ...

Najat Khan looks at successful platform companies like Vertex, Regeneron and Alnylam and sees a path for Recursion to join them—if the company stays disciplined. (Recursion Pharmaceuticals) Chris ...